Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bemcentinib||BGB 324|BGB-324|BGB324|R428|R-428||AXL Inhibitor 29||Bemcentinib (BGB-324) is a small molecule inhibitor of Axl, which inhibits tumor growth and may overcome EMT-mediated acquired drug resistance (PMID: 20145120, PMID: 31134766).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||chronic myeloid leukemia||not applicable||Bemcentinib||Preclinical - Patient cell culture||Actionable||In a preclinical study, treatment with Bemcentinib (BGB-324) inhibited Axl signaling, and resulted in growth inhibition and apoptosis in BCR-ABL1 positive chronic myeloid leukemia cell lines and patient-derived primary cells in culture (PMID: 27856601).||27856601|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03965494||Phase I||Bemcentinib||AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery||Recruiting||USA||0|
|NCT02488408||Phase I||Cytarabine Bemcentinib||Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML||Unknown status||USA||2|